Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
20,67 USD | -0,67% | -11,74% | -10,56% |
07/03 | Sectorupdate: Gezondheidszorgaandelen gemengd voor de beurs op donderdag | MT |
07/03 | Transcript : EyePoint Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024 |
Vakgebied
Aantal werknemers: 121
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
License and Collaboration Agreements
66,9
%
| 0 | 0,9 % | 31 | 66,9 % | +8.407,46% |
Ophthalmic Products
30,9
%
| 40 | 96,4 % | 14 | 30,9 % | -64,34% |
Royalty
2,1
%
| 1 | 2,7 % | 1 | 2,1 % | -13,02% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
98,4
%
| 40 | 97,8 % | 45 | 98,4 % | +11,83% |
China
1,4
%
| 1 | 2,0 % | 1 | 1,4 % | -21,26% |
United Kingdom
0,2
%
| 0 | 0,2 % | 0 | 0,2 % | 0,00% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 66 | 27-09-16 |
George Elston
DFI | Director of Finance/CFO | 59 | 14-11-19 |
Said Saim
CTO | Chief Tech/Sci/R&D Officer | 66 | 10-06-19 |
Jennifer Leonard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Nancy Lurker
BRD | Director/Board Member | 66 | 15-09-16 |
General Counsel | - | 07-03-22 | |
Michael Pine
PRN | Corporate Officer/Principal | - | 07-01-22 |
Scott Jones
PRN | Corporate Officer/Principal | 57 | 10-06-19 |
Ron I. Honig
LAW | General Counsel | - | 27-11-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 66 | 27-09-16 |
Wendy DiCicco
BRD | Director/Board Member | 56 | 15-07-19 |
David Guyer
BRD | Director/Board Member | 64 | 25-01-19 |
Anthony Adamis
BRD | Director/Board Member | 65 | 23-06-22 |
Nancy Lurker
BRD | Director/Board Member | 66 | 15-09-16 |
Chairman | 75 | 27-06-18 | |
John Landis
BRD | Director/Board Member | 71 | 25-10-18 |
Karen Zaderej
BRD | Director/Board Member | 62 | 11-07-22 |
Stuart Duty
BRD | Director/Board Member | 59 | 16-10-23 |
Ye Liu
BRD | Director/Board Member | 53 | 01-01-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 49 830 792 | 48 731 637 ( 97,79 %) | 0 | 97,79 % |
Bedrijfsgegevens
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street Suite A-210
02472, Watertown
+617 926 5000
http://www.eyepointpharma.comSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-10,56% | 1,03 mld. | |
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+0,74% | 209 mld. | |
+2,95% | 212 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |
- Beurs
- Aandelen
- Aandeel EyePoint Pharmaceuticals, Inc. - Nasdaq
- Onderneming EyePoint Pharmaceuticals, Inc.